Sumitomo Pharma And Otsuka Announce Topline Results From Phase 3 Diamond1 And Diamond2 Clinical Studies Evaluating Ulotaront In Schizophrenia
31/07/2023 05:12
July 31 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* SUMITOMO PHARMA CO LTD - SUMITOMO PHARMA AND OTSUKA
ANNOUNCE
TOPLINE RESULTS FROM PHASE 3 DIAMOND1 AND DIAMOND2 CLINICAL
STUDIES EVALUATING ULOTARONT IN SCHIZOPHRENIA
Source text for Eikon: ID:nTSsd81479
Further company coverage: 4506.T
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)